A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Key Inclusion Criteria Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent Diagnosis of mature aggressive large B cell non-Hodgkin lymphoma or Follicular lymphoma Grade 3B Tumor must be cluster of differentiation (CD) 20 positive by immunohistochemistry Have relapsed or refractory disease after >= 2 lines of standard therapy and relapsed within 12 months of last therapy Measurable disease as defined by Lugano 2014 classification Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 Key Exclusion Criteria Diagnosis of Human herpes virus (HHV) 8-positive Diffuse large B Cell lymphoma (DLBCL) Prior allogeneic Hematopoietic stem cell transplantation (HSCT) Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion Uncontrolled active infections History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT]) History of stroke, unstable angina, myocardial infarction, congestive heart failure ( New York Heart Association [NYHA] Class III or IV), severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or neurodegenerative disorder Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system Active central nervous system (CNS) involvement by malignancy Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)